Page 1

Exhibit 99.1 Cervo Med Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies ( DLB ) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway ( ILAP ) for development in DLB New analyses presented at the Alzheimer's Association International Conference ( AAIC ) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial , 12 - week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia ( nfvPPA ) to be presented at the 15th International Conference on Frontotemporal Dementia ( ISFTD ) in October 2026 ; full 12 - week and initial , 24 - week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease ( CTAD ) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $ 20.5 million , extending cash runway through the third quarter of 2027 BOSTON , August 10 , 2026 - CervoMed Inc. ( NASDAQ : CRVO ) , a clinical - stage biotechnology company developing treatments for age - related brain disorders ( CervoMed or the Company ) , today reported financial results for the second quarter ended June 30 , 2026 , and provided corporate updates . " The second quarter was marked by meaningful progress across both our business and pipeline . The additional analyses presented at AAIC 2026 further strengthen our conviction in neflamapimod's potential as a meaningful , disease - modifying treatment for DLB . These findings provide important insight into the RewinD - LB results , reinforce the treatment effect observed in patients with pure DLB , and support selection of the 50 mg three - times - daily ( TID ) dose for our planned Phase 3 trial . Looking ahead , our primary strategic objective is securing a partner to support the advancement of neflamapimod into Phase 3 and realize its potential for patients living with DLB , ” said John Alam , MD , Chief Executive Officer of Cervo Med . Dr. Alam continued , “ We are also excited by the continued progress in our nfvPPA program . The trends observed in the 12 - week biomarker data from the initial eight participants in our ongoing Phase 2a clinical trial are highly encouraging and we're honored to have the opportunity to share those results with the frontotemporal dementia ( FTD ) community at ISFTD in October . We also look forward to reporting additional biomarker data from the trial at CTAD in November . We believe nfvPPA represents a significant and underappreciated opportunity for neflamapimod . "